


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN	OMARIGLIPTIN
PRONUNCIATION	oh mar" i glip' tin
THERAPEUTIC CLAIM	Treatment of type 2 diabetes

CHEMICAL NAMES

1. 2*H*-Pyran-3-amine, 2-(2,5-difluorophenyl)-5-[2,6-dihydro-2-(methylsulfonyl)pyrrolo[3,4-*c*]pyrazol-5(4*H*)-yl]tetrahydro-, (2*R*,3*S*,5*R*)-
2. (2*R*,3*S*,5*R*)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-*c*]pyrazol-5(4*H*)-yl]tetrahydro-2*H*-pyran-3-amine
3. (2*R*,3*S*,5*R*)-2-(2,5-difluorophenyl)-5-[2-(methanesulfonyl)-2,6-dihydropyrrolo[3,4-*c*]pyrazol-5(4*H*)-yl]oxan-3-amine

STRUCTURAL FORMULA



MOLECULAR FORMULA	C ₁₇ H ₂₀ F ₂ N ₄ O ₃ S
MOLECULAR WEIGHT	398.43
TRADEMARK	None as yet
SPONSOR	Merck Sharp & Dohme Corp.
CODE DESIGNATION	None
<u>CAS</u> REGISTRY NUMBER	1226781-44-7